Edgewise Therapeutics Inc., a biopharmaceutical company specializing in muscle diseases, has released its financial results for the second quarter of 2025. The company reported a net loss of $36.1 million, or $0.34 per share, an improvement from the $40.8 million, or $0.43 per share, loss recorded in the previous quarter. Research and development expenses decreased to $33.6 million from $36.8 million in the prior quarter, driven by reductions in clinical development activities for sevasemten and EDG-7500, as well as lower personnel-related costs due to previously higher stock-based compensation. However, there was an increase in manufacturing expenses to support clinical development across the company's programs. Edgewise Therapeutics highlighted recent business progress, including positive top-line data from trials involving sevasemten in Becker and Duchenne muscular dystrophies and advancement of the Phase 2 CIRRUS-HCM trial for EDG-7500 in Hypertrophic Cardiomyopathy. Additionally, the company plans to initiate a Phase 1 trial for EDG-15400, a novel drug candidate for heart failure, in the third quarter of 2025. As of June 30, 2025, Edgewise Therapeutics reported cash, cash equivalents, and marketable securities totaling approximately $594.0 million. The company remains active in its engagement with the scientific and patient communities, participating in various conferences and events related to muscular dystrophy and heart conditions.